Can Xtandi Become the Go-To Prostate Drug?
A slew of new prostate cancer drugs offer treatment options for advance prostate cancer patients. But Xtandi could become a solution for early stage too.
Approval? Check. Partner? Not So Much.
Dendreon gains EU approval for Provenge, but it needs a partner.
A Big Boost or False Hope For This Biotech?
Dendreon's Provenge received approval in the EU. Is this a major opportunity for the struggling biotech?
Market Checkup: September 17, 2013
Decisions from the EU's regulatory agency and a dividend stock to watch.
Will the Exelixis Hype Catch Up to Its Valuation?
Investors have high hopes for Exelixis' cancer drug Cometriq. But whether it can grow into its current valuation remains to be seen.
No Generic Zytiga Benefits Medivation
Big news for prostate cancer companies.